Drugs / XL495
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06630247 | Oct 2024 → May 2025 | metastatic malignant neoplasm, renal pelvis urothelial carcinoma | Exelixis | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XL495 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06630247 ↗ |
| Route | Oral | “oral doses of XL495” NCT06630247 ↗ |